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Live Case Demonstration
of Interventional
Cardiology Procedures
A Regulatory Perspective*
Andrew Farb, MD, Bram Zuckerman, MD
Silver Spring, Maryland
Medical science progress requires a strong educational founda-
tion, and the direct demonstration of knowledge and skills
has been a traditional teaching method for practitioners.
Advances in communication technology have provided un-
precedented opportunities to show patient care in real time.
As a result, there has been proliferation of live case presen-
tations to audiences attending professional society confer-
ences and worldwide via the Internet.
Despite the popularity of live cases, their educational
value is uncertain and difficult to measure. There are
associated medical ethics issues, the most important being
whether participation in a live case is in a patient’s best
interest. Critics of live cases point to their “entertainment”
quality. Further, concerns have been raised that live cases
may be associated with increased patient safety risks. In
addition, patient confidentiality may be inadvertently com-
promised during the broadcast.
See pages 215 and 228
Professional society groups representing thoracic sur-
geons and cardiologists have each published position papers
on live cases. Citing important safety risks against limited
educational benefits, 2 thoracic surgery societies recom-
mended that live surgery broadcasts should be prohibited at
their professional society meetings (1). In contrast, a con-
sortium of cardiovascular professional societies emphasized
the benefits live cases, including physician education, im-
proved medical care, promotion of clinical trials, and med-
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designed to lower patient risks and enhance educational
value (2).
A major obstacle to understanding the risks associated
with live cases is the paucity of clinical study data (3,4). In
this issue of JACC: Cardiovascular Interventions, Eliyahu
et al. (5) provide important new information regarding live
broadcasts of interventional cardiology procedures. They
reviewed 101 live interventional cardiovascular cases per-
formed between 1998 and 2010. The format consisted of 1
or more operators discussing the procedure with an off-site
expert panel. The complete procedural success rate was 83%.
With regard to safety, the major complication rate was 2%
(2 of 101 cases). However, among the procedural compli-
cations that were considered “minor” were 3 cases of
ventricular fibrillation, 1 case of guidewire-induced coronary
perforation, 2 access site bleeds, and 1 case of pericardial
tamponade. The authors compared outcomes to a case-
matched control group; there were no statistically significant
differences in the procedural success and complications
rates. However, confidence intervals were quite wide, and
the study was a retrospective analysis of a very select
single-center registry.
The FDA Perspective
The broad regulatory mission of the U.S. Food and Drug
Administration (FDA) is to promote and protect public
health, and the role of the FDA’s Center for Devices and
Radiologic Health is to ensure the safety and effectiveness of
medical devices. Once a device is FDA approved, it may
used by a physician for its approved indication or outside of
its approved indication (known as off-label use) as part of
the “practice of medicine,” which is not regulated by the
FDA. Therefore, with regard to live cases, the FDA’s major
regulatory oversight is on the use of investigational, non-
FDA-approved devices, which are undergoing evaluation in
an ongoing FDA-approved investigational device exemp-
tion (IDE) study. An IDE allows the use of investigational
devices in a clinical study, which is often designed to collect
safety and effectiveness data to support marketing in the
United States.
The FDA defines a live case presentation as: “Treatment
of a human subject under the auspices of an approved or
conditionally approved IDE, conducted and broadcast in
real time, or taped for broadcast at a later time.” The FDA
is developing a guidance document on live case presenta-
tions performed during IDE studies.
To use an investigational device in a live case presenta-
tion, a sponsor must request approval from the FDA.
Because an investigational device often may only be avail-
able for use in an ongoing IDE study (i.e., it is not available
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226to all U.S. physicians and patients), and may potentially
never be FDA-approved for general use, the use of an
investigational device in a live case is justified in limited
circumstances. The FDA will permit the use of an investi-
gational device in a live case to increase awareness of the
IDE study for investigators and potential investigators and
to facilitate the recruitment of subjects. These criteria are
consistent with the FDA’s objective to facilitate the timely
completion of clinical studies to capture safety and effec-
tiveness data needed for FDA approval that results in the
availability of beneficial devices for U.S. patients. A inves-
tigational device being used in an IDE study that is rapidly
enrolling or nearing complete enrollment would not be
appropriate for a live case presentation; live case use in these
circumstances would be viewed as essentially promotional in
nature. During live case demonstrations, the devices should
be clearly identified as investigational, and comments by
operators and panel members, in addition to ancillary presenta-
tion materials, should not be used for commercial promo-
tion of the device.
In the evaluation of an application for a live case demonstration
of an investigational device, the FDA focuses its review on 3
critical patient protection components: 1) Institutional Review
Board approval; 2) a comprehensive risk analysis and risk mitiga-
tion strategy; and 3) the informed consent document.
By definition, the safety and effectiveness of an investi-
gational device has not been established, and study patients
consent to enrollment even though all risks are not com-
pletely known. The application for a live case demonstration
of an investigational device must include a comprehensive
discussion of potential risks beyond the risks of the study
device and procedure. Potential concerns may include in-
creased risk of infection; prolongation of the procedure
leading to increased anesthesia, contrast use, and radiation
exposure; distraction of the operator leading to complica-
tions; and disclosure of the patient’s privileged information.
The application should include patient-protection measures
that mitigate those risks as much as possible. These may
consist of live procedures performed by highly experienced
operators at their home institutions, use of study sites
familiar with live cases, and the use of an on-site discussant
(rather than the primary operator) that interacts with the
off-site panel. A live case–specific informed consent is
required that includes language on risks. Patients should
also be informed that they should expect no additional
clinical benefit from their participation in a live case.
For IDE studies, patient participation in live cases cannot
come at the expense of study integrity or the interpretability of
study data. Subjects in live cases “count” toward total number
of patients permitted, and the outcomes of these subjects are
considered in the analysis of study results. Sponsors who
anticipate live cases should account for these subjects in the
total sample size of the study. To preserve the study’s scientific
validity, live case patients must fulfill the same inclusion/exclusion criteria and must be treated and followed in the same
manner (including adjunctive standard-of-care treatments) as
all nonlive case subjects. Live case participants need to be
pre-selected, but identification of appropriate patients must not
result in selection bias. The potential effect of pre-selection on
study parameters, such as randomization and blinding (where
applicable), needs to be considered. In some cases, it may be
appropriate to exclude data from live cases from the primary
study analysis. Sponsors are required to submit reports to the
FDA that detail clinical results of live cases and compare
outcomes in live case subjects to the nonlive case study population.
The FDA does not regulate the use of approved medical
devices in live case demonstrations. However, similar to live case
presentations of investigational devices, use of approved devices in
live cases should not be for commercial promotion. An additional
concern is that the presentation could be interpreted as endorsing
off-label use of a product. Any off-label use of a device should be
clearly identified during the live case, and the FDA has the
authority to take disciplinary action for commercial promotion of
off-label use of a medical device.
Some procedures (e.g., extremely high-risk procedures or
compassionate use procedures) are not appropriate for live
case presentations of investigational devices. Further, live
cases using investigational devices in children require addi-
tional considerations. Because technical challenges and pro-
cedural risks are likely to be higher in children than in
adults, and there is no expectation of direct benefit by
participation, live cases in children should be limited to
those that present no more than minimal risk.
The Center for Devices and Radiologic Health does not
regulate the use of investigational devices used in live cases
performed at non-U.S. sites and broadcast to a conference
within the United States. In these circumstances, sponsors
follow the regulations applicable to the country in which the
live case is being performed. However, the FDA recom-
mends that all live cases, irrespective of where they are
conducted, apply high standards of medical ethics and
incorporate essential patient-protection measures (risk anal-
ysis, risk mitigation, and informed consent).
Conclusions
The study by Eliyahu et al. (5) provides some reassurance that
live case presentations of interventional cardiology procedures
do not appear to be associated with significantly increased risks
to patients. However, data are quite limited, and further studies
are warranted. An international registry of prospectively col-
lected data from live cases presented at major interventional
cardiology meetings would greatly enhance our understanding
of risks and could lead to additional measures to reduce those
risks. In addition, establishment of the educational value of live
cases, though challenging to assess, would support their pre-
sumed benefit to medical care.
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227For investigational devices, the FDA will continue its
important regulatory role to ensure that all live cases using
investigational devices are appropriately selected to aid in
the completion of an IDE study, are nonpromotional, and
address and mitigate potential risks to patients.
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